News

EUSA Pharma has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

The technology acquired consist a platform technology referred to by MDC as DIAAD™ and certain monoclonal antibody candidates to detect and treat cancer.

NCI scientists have discovered an antibody that neutralizes two highly infectious viruses classified as henipaviruses.

Company will present the Phase 1 data with Picoplatin in metastatic prostrate cancer patients at the 2008 Genitourinary (GU) Cancers Symposium.

Scientists at The Wistar Institute have collaborated on a major advance in understanding a gene regulator that contributes to some of the deadliest cancers in humans.

The new strategy aims to reduce reliance on animal testing, according to scientists.

Under the theme “Moving Science Forward”, the company will demonstrate a range of analytical instruments, software and laboratory workflow solutions.

AstraZeneca and Nomura Phase4 Ventures sign a deal to form a company focused on developing new treatments for gastrointestinal (GI) disorders.

BioDynamics, a specialist provider of metabolism, bioanalytical and radiochemistry services, represents the fourth acquisition to date for Quotient BioResearch.

Biomoda and Medical Acoustics will collect lung sputum samples in an upcoming clinical study that will use Biomoda's proprietary testing technology for detection of early lung cancer.